Press Release

Collaboration Research Agreement for a multispecific antibody candidate with NumabJune 13, 2017

Tokyo, June 13, 2017 – Kaken Pharmaceutical Co., Ltd. (“Kaken”, head office Bunkyo-ku, Tokyo; President and Representative Director Tetsuo Onuma) announced that it have enterd into a collaboration research agreement with Numab Therapeutics AG (“Numab”) for the identification of a multispecific antibody candidate for development in inflammatory disease.


Under the agreement, Kaken will obtain an option to conclude a license and co-development agreement after identification of lead candidate generated by Numab using its unique multispecific antibody technology platform. Kaken is to fully fund the research program.


About Numab
Founded in 2011, Numab develops a proprietary pipeline of multi-specific biotherapeutics in immuno-oncology and immunology, and has a number of discovery partnerships with pharmaceutical companies. Numab’s plug-and-play multi-specifics platform allows for a highly rational and reproducible process that rapidly yields promising clinical candidates with new mechanisms of action, superior efficacy and a favorable safety profile. Numab is represented in Japan by PharmaBDL. For further information, visit

Back to list